{"links": [{"source": 0, "target": "t1482", "value": "None"}, {"source": 0, "target": "t1489", "value": "None"}, {"source": 0, "target": "t1500", "value": "None"}, {"source": 0, "target": "t1496", "value": "None"}, {"source": "t1482", "target": "t1485", "value": "None"}, {"source": "t1482", "target": "t1483", "value": "None"}, {"source": "t1482", "target": "t1484", "value": "None"}, {"source": "t1489", "target": "t1491", "value": "None"}, {"source": "t1489", "target": "t1490", "value": "None"}, {"source": "t1500", "target": "t1501", "value": "None"}, {"source": "t1500", "target": "t1506", "value": "None"}, {"source": "t1500", "target": "t1505", "value": "None"}, {"source": "t1484", "target": "t1486", "value": "None"}, {"source": "t1490", "target": "t1492", "value": "None"}, {"source": "t1490", "target": "t1497", "value": "None"}, {"source": "t1501", "target": "t1502", "value": "None"}, {"source": "t1486", "target": "t1488", "value": "None"}, {"source": "t1486", "target": "t1487", "value": "None"}, {"source": "t1492", "target": "t1493", "value": "None"}, {"source": "t1497", "target": "t1498", "value": "None"}, {"source": "t1502", "target": "t1503", "value": "None"}, {"source": "t1493", "target": "t1494", "value": "None"}, {"source": "t1493", "target": "t1495", "value": "None"}, {"source": "t1498", "target": "t1499", "value": "None"}, {"source": "t1503", "target": "t1504", "value": "None"}, {"source": "t1503", "target": "d410", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Stable_angina", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Stable_angina"}}, {"category": "treatment", "id": "t1482", "name": "person at risk of cardiovascular disease", "draggable": "true", "value": {"name": "person at risk of cardiovascular disease", "type": "treatment related", "time": "", "intention": "", "description": "title:person at risk of cardiovascular disease", "drug": {}}}, {"category": "treatment", "id": "t1489", "name": "person presenting with chest pain", "draggable": "true", "value": {"name": "person presenting with chest pain", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person presenting with chest pain", "drug": {}}}, {"category": "treatment", "id": "t1500", "name": "adult with suspected type 1 diabetes", "draggable": "true", "value": {"name": "adult with suspected type 1 diabetes", "type": "treatment related", "time": "", "intention": "", "description": "title:adult with suspected type 1 diabetes", "drug": {}}}, {"category": "treatment", "id": "t1496", "name": "myocardial infarction: rehabilitation and preventing further cardiovascular disease", "draggable": "true", "value": {"name": "myocardial infarction: rehabilitation and preventing further cardiovascular disease", "type": "treatment related", "time": "", "intention": "", "description": "title:myocardial infarction: rehabilitation and preventing further cardiovascular disease", "drug": {}}}, {"category": "treatment", "id": "t1485", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t1483", "name": "people at risk of dying early from cardiovascular disease", "draggable": "true", "value": {"name": "people at risk of dying early from cardiovascular disease", "type": "treatment related", "time": "", "intention": "", "description": "title:people at risk of dying early from cardiovascular diseasehead:People at risk of dying early from cardiovascular diseaseSee what NICE says on identifying and supporting people most at risk of dying early from cardiovascular disease. These recommendations aim to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.The recommendations cover adults who are disadvantaged: who smoke and/or who are eligible for statins and/or who are at high risk of CVD due to other factors.", "drug": {}}}, {"category": "treatment", "id": "t1484", "name": "identification and assessment", "draggable": "true", "value": {"name": "identification and assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:identification and assessment", "drug": {}}}, {"category": "treatment", "id": "t1491", "name": "patient experience in adult nhs services", "draggable": "true", "value": {"name": "patient experience in adult nhs services", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience in adult nhs services", "drug": {}}}, {"category": "treatment", "id": "t1490", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportDiscuss any concerns people (and where appropriate their family or carer/advocate) may have, including anxiety when the cause of the chest pain is unknown. Correct any misinformation.Offer people a clear explanation of the possible causes of their symptoms and the uncertainties.Clearly explain the options to people at every stage of investigation. Make joint decisions with them and take account of their preferences: Encourage people to ask questions. Provide repeated opportunities for discussion. Explain test results and the need for any further investigations.Provide information about any proposed investigations using everyday, jargon-free language. Include: their purpose, benefits and any limitations of their diagnostic accuracy duration level of discomfort and invasiveness risk of adverse events.Offer information about the risks of diagnostic testing, including any radiation exposure.Address any physical or learning difficulties, sight or hearing problems and difficulties with speaking or reading English, which may affect people s understanding of the information offered.Offer information after diagnosis as recommended in the relevant disease management guidelines. For example, see NICE s recommendations on early management of unstable angina and NSTEMI and managing stable angina, dyspepsia and gastro-oesophageal reflux disease and generalised anxiety disorder.Explain if the chest pain is non-cardiac and refer people for further investigation if appropriate.Provide individual advice to people about seeking medical help if they have further chest pain.NICE has written information for the public on chest pain.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG95", "drug": {}}}, {"category": "treatment", "id": "t1501", "name": "diagnosis", "draggable": "true", "value": {"name": "diagnosis", "type": "treatment related", "time": "", "intention": "", "description": "title:diagnosishead:DiagnosisDiagnose type 1 diabetes on clinical grounds in adults presenting with hyperglycaemia, bearing in mind that people with type 1 diabetes typically (but not always) have one or more of: ketosis  rapid weight loss age of onset below 50 years BMI below 25 kg/m2 personal and/or family history of autoimmune disease.Do not discount a diagnosis of type 1 diabetes if an adult presents with a BMI of 25 kg/m2 or above or is aged 50 years or above.Do not measure C-peptide and/or diabetes-specific autoantibody titres routinely to confirm type 1 diabetes in adults. Consider further investigation in adults that involves measurement of C-peptide and/or diabetes-specific autoantibody titres if: type 1 diabetes is suspected but the clinical presentation includes some atypical features (for example, age 50 years or above, BMI of 25 kg/m2 or above, slow evolution of hyperglycaemia or long prodrome) or type 1 diabetes has been diagnosed and treatment started but there is a clinical suspicion that the person may have a monogenic form of diabetes, and C-peptide and/or autoantibody testing may guide the use of genetic testing or classification is uncertain, and confirming type 1 diabetes would have implications for availability of therapy (for example, continuous subcutaneous insulin infusion [CSII or  insulin pump ] therapy). When measuring C-peptide and/or diabetes-specific autoantibody titres, take into account that: autoantibody tests have their lowest false negative rate at the time of diagnosis, and that the false negative rate rises thereafter C-peptide has better discriminative value the longer the test is done after diagnosis with autoantibody testing, carrying out tests for 2 different diabetes-specific autoantibodies, with at least 1 being positive, reduces the false negative rate.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG17", "drug": {}}}, {"category": "treatment", "id": "t1506", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t1505", "name": "medicines optimisation", "draggable": "true", "value": {"name": "medicines optimisation", "type": "treatment related", "time": "", "intention": "", "description": "title:medicines optimisation", "drug": {}}}, {"category": "treatment", "id": "t1486", "name": "cardiovascular disease prevention", "draggable": "true", "value": {"name": "cardiovascular disease prevention", "type": "treatment related", "time": "", "intention": "", "description": "title:cardiovascular disease prevention", "drug": {}}}, {"category": "treatment", "id": "t1492", "name": "acute chest pain", "draggable": "true", "value": {"name": "acute chest pain", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:acute chest pain", "drug": {}}}, {"category": "treatment", "id": "t1497", "name": "stable chest pain", "draggable": "true", "value": {"name": "stable chest pain", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:stable chest pain", "drug": {}}}, {"category": "treatment", "id": "t1502", "name": "support and individualised care", "draggable": "true", "value": {"name": "support and individualised care", "type": "information and support", "time": "", "intention": "", "description": "title:support and individualised carehead:Support and individualised careTake account of any disabilities, including visual impairment, when planning and delivering care for adults with type 1 diabetes.Advice to adults with type 1 diabetes should be provided by a range of professionals with skills in diabetes care working together in a coordinated approach. A common environment (diabetes centre) is an important resource in allowing a diabetes multidisciplinary team to work and communicate efficiently while providing consistent advice. Provide adults with type 1 diabetes with: open-access services on a walk-in and telephone-request basis during working hours a helpline staffed by people with specific diabetes expertise on a 24-hour basis contact information for these services.Regard each adult with type 1 diabetes as an individual, rather than as a member of any cultural, economic or health-affected group (see also recommendations about the cultural preferences of individual adults with type 1 diabetes in dietary management and insulin regimens).Use population, practice-based and clinic diabetes registers (as specified by the National service framework for diabetes) to assist programmed recall for annual review and assessment of complications and cardiovascular risk. Also see delivery of care in care in hospital.NICE has written information for the public on type 1 diabetes in adults: diagnosis and management.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG17", "drug": {}}}, {"category": "treatment", "id": "t1488", "name": "lipid modification therapy", "draggable": "true", "value": {"name": "lipid modification therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:lipid modification therapy", "drug": {}}}, {"category": "treatment", "id": "t1487", "name": "lifestyle changes", "draggable": "true", "value": {"name": "lifestyle changes", "type": "information and support", "time": "", "intention": "", "description": "title:lifestyle changes", "drug": {}}}, {"category": "treatment", "id": "t1493", "name": "assessment and immediate management of suspected acs", "draggable": "true", "value": {"name": "assessment and immediate management of suspected acs", "type": "treatment related", "time": "", "intention": "", "description": "title:assessment and immediate management of suspected acs", "drug": {}}}, {"category": "treatment", "id": "t1498", "name": "assessing and diagnosing stable angina", "draggable": "true", "value": {"name": "assessing and diagnosing stable angina", "type": "treatment related", "time": "", "intention": "", "description": "title:assessing and diagnosing stable angina", "drug": {}}}, {"category": "treatment", "id": "t1503", "name": "early care plan", "draggable": "true", "value": {"name": "early care plan", "type": "information and support", "time": "", "intention": "albumin\nit is used to treat or prevent low blood volume.\nit is used to treat low blood pressure.\nit is used to replace albumin in people with low blood albumin levels.\nit is used to add back fluid after fluid loss.\nit is used to treat shock.", "description": "title:early care planhead:Early care planAt the time of diagnosis (or if necessary after the management of critically decompensated metabolism), the diabetes professional team should develop with and explain to the adult with type 1 diabetes a plan for their early care. To agree such a plan will generally require: medical assessment to: ensure security of diagnosis of type of diabetes ensure appropriate acute care is given when needed review and detect potentially confounding disease and medicines detect adverse vascular risk factors environmental assessment to understand: the social, home, work and recreational circumstances of the person and carers their preferences in nutrition and physical activity other relevant factors, such as substance use cultural and educational assessment to identify prior knowledge and to enable optimal advice and planning about: treatment modalities diabetes education programmes assessment of emotional state to determine the appropriate pace of educationThe results of the assessment should be used to agree a future care plan. Some items of the initial diabetes assessment: acute medical history social, cultural and educational history/lifestyle review complications history/symptoms long-term/recent diabetes history other medical history/systems family history of diabetes/cardiovascular disease medication history/current medicines vascular risk factors smoking general examination weight/BMI foot/eye/vision examination urine albumin excretion/urine protein/serum creatinine psychological wellbeing attitudes to medicine and self-care immediate family and social relationships and availability of informal support.Elements of an individualised and culturally appropriate plan will include: sites and timescales of diabetes education, including nutritional advice (see education and information and dietary management) initial treatment modalities, including guidance on insulin injection and insulin regimens (see insulin therapy for adults with type 1 diabetes) means of self-monitoring and targets (see blood glucose measurement and targets) symptoms, risk and treatment of hypoglycaemia management of special situations, such as driving means and frequency of communication with the diabetes professional team management of cardiovascular risk factors (see managing cardiovascular disease risk in adults with type 1 diabetes) for women of childbearing potential, implications for pregnancy and family planning advice (see what NICE says on diabetes in pregnancy) frequency and content of follow-up consultations, including review of HbA1c levels and experience of hypoglycaemia, and annual review.After the initial plan is agreed, put arrangements in place to implement it without inappropriate delay, and to provide for feedback and modification of the plan over the ensuing weeks. At the time of diagnosis and periodically thereafter, provide adults with type 1 diabetes with up-to-date information about diabetes support groups (local and national), how to contact them and the benefits of membership. Also see associated illness in individual care plan.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG17", "drug": {}}}, {"category": "treatment", "id": "t1494", "name": "unstable angina and nstemi", "draggable": "true", "value": {"name": "unstable angina and nstemi", "type": "treatment related", "time": "", "intention": "", "description": "title:unstable angina and nstemi", "drug": {}}}, {"category": "treatment", "id": "t1495", "name": "myocardial infarction with st segment elevation", "draggable": "true", "value": {"name": "myocardial infarction with st segment elevation", "type": "treatment related", "time": "", "intention": "", "description": "title:myocardial infarction with st-segment elevation", "drug": {}}}, {"category": "treatment", "id": "t1499", "name": "managing stable angina", "draggable": "true", "value": {"name": "managing stable angina", "type": "treatment related", "time": "", "intention": "", "description": "title:managing stable angina", "drug": {}}}, {"category": "treatment", "id": "t1504", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "drug", "id": "d410", "name": "albumin", "draggable": "true", "value": {"name": "albumin", "time": "None", "period": "None", "dosage": "None"}}]}